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Introduction
Follicular lymphoma (FL) is one of the most common subtypes of
lymphoma in Western countries, accounting for 10-20% of all
newly diagnosed non-Hodgkin’s lymphomas. Clinical course of FL
is typically indolent, with impressive responses to initial treatments.
Nevertheless, frequent relapses with shorter remission duration
occur that need additional therapeutic interventions and increase
the risk of drug resistance.
Treatment options for treatment-naive or recurring follicular lym-
phoma patients are still controversial, ranging from watch and wait
to hematopoietic stem-cell transplantation. When a treatment is
indicated, chemotherapy is usually prescribed. In most recent years,
the advent of anti CD20 monoclonal antibody Rituximab (R) has
dramatically changed the approach to this disease, and immu-
nochemotherapy is at present considered the standard of care for
patients diagnosed with high tumor burden FL, leading at advances
in Progression Free Survival ( PFS) and Overall Survival(OS)1e3.
Discussion
In order to prolong remission duration, the use of maintenance
strategies after the first treatment has been considered over a long
time. The use of interferon was first evaluated, showing benefits in
terms of duration of remission and survival4; however, the safety
profile of the drug and the low manageability of treatment has led
most physicians to abandon this treatment option.
The availability of rituximab as an effective and low toxic single
agent has suggested to explore the possibility to use it not only to
improve efficacy of chemotherapy in first line therapy, but also to
delay progression after initial treatment reflecting the ideal main-
tenance strategy which involve clinical benefit, good tolerance and
convenient administration.
The PRIMA trial clearly showed that rituximab maintenance in
patients achieving a response to initial chemoimmunotherapy resultsS104in an improved outcome in terms of prolonged PFS and made a step
forward in the management of patients with FL5. However, one
important question that can be raised is whether this approach is
really needed for all patients with FL or if some of them could
benefit from a risk adapted maintenance strategy, intensifying
treatment in those recognized at high risk of recurrence, and
reducing it in patients at lower risk. For example, in patients with
low tumor burden who received front line rituximab, the RESORT
study clearly showed that retreatment with rituximab instead rit-
uximab maintenance was associated with an excellent outcome
(86% chemotherapy free at 3 years), lack of Quality of Life dif-
ference and fewer rituximab doses required. 6
Recently, response to therapy assessed either with fluorodeox-
yglucose-positron emission tomography (PET) or with highly sen-
sitive molecular techniques targeting the t(14;18) chromosomal
translocation (Minimal residual disease e MRD) have been sug-
gested as important prognostic factors and are both identified as
pivotal tools to achieve the goal of personalized treatment. The
predictive value of PET and MRD is clearly recognized based on a
large bulk of published evidence, and might be used to better
tailoring post induction treatment in patients achieving satisfactory
response with rituximab containing regimens.
Post-induction FDG-PET provides powerful prognostic informa-
tion in FL. About 80-85% of patients achieve a complete metabolic
response (CMR) following immunochemotherapy and have an
excellent outcome irrespective of whether rituximab maintenance is
given (w95% survival at 6 years). In contrast, the w15-20% of
patients who fail to achieve a CMR are expected to have a signifi-
cantly worse outcome.7, 8
Several studies indicate that, regardless to the treatment adminis-
tered, the absence in the bone marrow and peripheral blood of
neoplastic cells bearing the bcl-2/IgH rearrangement during the
follow-up was strongly associated with a reduced risk of recurrence,
clearly suggesting the need for MRD detection in FL 9e12
In the year 2012 the Fondazione Italiana Linfomi (FIL) launched
the prospective randomized FOLL12 trial, with the aim of verifying
whether combining clinical response assessed on FDG-PET scan
and molecular response measured through MRD detection could
permit to single out patients at different risk of progression and to
consequently modulate maintenance.
In April, 2018 the planned accrual has been reached, with the
accrual of 807 cases. Patients randomized to standard Arm received
two years of rituximab maintenance according to the PRIMA
schedule. Those in the experimental Arm and at low risk defined by
post induction PET and MDR negativity, did not receive any
further maintenance; however, 4 weekly doses of rituximab were
allowed in case of MDR positivity during follow-up, for a maximum
of three re-treatments. On the contrary, patients at high risk (post
induction PET positive), received intensified maintenance with
(90)Y Ibritumomab Tiuxetan followed by rituximab maintenance for
2 years.
Some very preliminary analyses of the study will be presented at
conference site.
Conclusion
Despite rituximab maintenance has shown its beneficial effect in
prolonging PFS, its ability in improving OS is still questionable. In
this context we believe that the results of the FOLL12 study would
provide a more rationale use of currently available diagnostic and
therapeutic resources, thus offering the opportunity of better
tailoring maintenance therapy in patients responding to first line
chemoimmunotherapy.
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